1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one (Compound)

Description: A compound in the knowledge graph

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one's neighborhood in the knowledge graph.

Submit

Knowledge Graph Assertions

Source	Relation	Target	Evidence
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	Positively regulates Knowledge Graph Relation (Entity type)	AMIGO2 Gene (Entity type)	0.0062042703
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	dactolisib Compound (Entity type)	0.8716692328453064
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	Positively regulates Knowledge Graph Relation (Entity type)	HES1 Gene (Entity type)	0.0046971543
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	(5-(2-((2R,6S)-2,6-dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol Compound (Entity type)	0.8209730386734009
SID103905586 Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	0.2618992030620575
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Serine/threonine-protein kinase mTOR Protein (Entity type)	IC50
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	Negatively regulates Knowledge Graph Relation (Entity type)	ALDOC Gene (Entity type)	-0.006425097
(5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	0.8778050541877747
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	Negatively regulates Knowledge Graph Relation (Entity type)	IDI1 Gene (Entity type)	-0.007239664
OSI-027 Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one Compound (Entity type)	0.8064727187156677

1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
Positively regulates
Knowledge Graph Relation (Entity type)
AMIGO2
Gene (Entity type)
0.0062042703

1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
dactolisib
Compound (Entity type)
0.8716692328453064

1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
Positively regulates
Knowledge Graph Relation (Entity type)
HES1
Gene (Entity type)
0.0046971543

1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
(5-(2-((2R,6S)-2,6-dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
Compound (Entity type)
0.8209730386734009

SID103905586
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
0.2618992030620575

1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Serine/threonine-protein kinase mTOR
Protein (Entity type)
IC50

1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
Negatively regulates
Knowledge Graph Relation (Entity type)
ALDOC
Gene (Entity type)
-0.006425097

(5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
0.8778050541877747

1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
Negatively regulates
Knowledge Graph Relation (Entity type)
IDI1
Gene (Entity type)
-0.007239664

OSI-027
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one
Compound (Entity type)
0.8064727187156677

DISPLAY PER PAGE

Knowledge Graph Assertions

	Source	Relation	Target	Evidence
Loading results...

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.